Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Greenhaven Road Capital 2026 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Greenhaven Road Capital)

Primary Source Intelligence • Q2 2026 Letter Analysis

Greenhaven Road Capital Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Greenhaven Road Capital. This analysis is provided for institutional research purposes only and is not investment advice.

SOURCE UNAVAILABLE

Fund Returns

QTD+11%

Positioning StanceConstructive

Market CapSmallCap

Digest Analysis

Quick Take

"Greenhaven Road is repositioning toward lower concentration and near-term catalysts while maintaining differentiated research focus."

Executive Summary

Greenhaven Road returned 11% net in Q2 2026 but remains below target performance levels. The manager is moderately adjusting portfolio construction toward lower concentration, more near-term catalysts, and greater profit-taking discipline while maintaining focus on advantaged businesses and differentiated research. The portfolio is unusually well-positioned with several top holdings facing identifiable events over the next year. Burford's protein price-fixing settlements could exceed its market cap as trials begin in 2027, yet remain largely unrecognized by analysts. Hagerty's State Farm partnership is accelerating faster than consensus expects, with potential Geico partnership emerging. Cellebrite's Genesis AI product positions it to shift from perceived AI loser to winner. Special situations at Compass Diversified, Lifecore, and AnaptysBio offer near-term resolution paths. New investments include catalyst-driven positions in CODI, LQDA, APP, and ANAB. The manager believes the portfolio backs swift and strong companies where non-consensus views will be tested within 12 months, not years, determining whether differentiated research produces exceptional returns or painful losses.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

The manager demonstrates high conviction through concentrated positions in Burford, Hagerty, Cellebrite, Lifecore, and Kingsway with detailed, specific theses for each. Position sizing is explicit ('full position' in Burford, 'top-five holding' for Lifecore). The letter provides falsifiable catalysts with timeframes (Burford trials 2027, Hagerty State Farm acceleration, Cellebrite Genesis revenue). However, the explicit shift toward lower concentration and the addition of smaller positions like 1% AppLovin indicate moderation from extreme conviction. The detailed analysis and willingness to hold through volatility support a score in the high-moderate range.

Growth Outlook

15%

BearishBullish

Bearish (15%)

The manager acknowledges sector rotation favoring AI hardware over software, insurance, and alternative assets where the fund is positioned. Multiple compression across holdings despite growth suggests challenging market conditions. However, the manager sees specific mispricings and catalyst opportunities rather than expressing broad market pessimism. The tone is selective and opportunity-focused within a difficult environment, warranting a mildly positive score.

Risk Appetite

45%

DefensiveAggressive

Balanced (45%)

The portfolio remains substantially invested with full positions in top holdings like Burford, Hagerty, and Cellebrite. Four new investments were initiated in Q2. However, the manager is explicitly shifting toward lower concentration and greater profit-taking discipline, evidenced by the Liquidia sale after 30% appreciation. This represents moderate risk appetite with tactical adjustments rather than aggressive deployment or defensive positioning.

Capital Deployment

35%

De-riskingDeploying

Net Neutral (35%)

Four new investments were initiated in Q2 (CODI, LQDA, APP, ANAB), indicating active deployment. However, Liquidia was sold after 30% appreciation, representing profit-taking. The manager describes maintaining 'full positions' in top holdings rather than adding to them. No cash level changes are disclosed. The activity represents selective rotation and new position building rather than net deployment of cash reserves, warranting a moderately positive score reflecting new position activity offset by profit-taking discipline.

Forward Guidance

50%

CautiousExpansionary

Neutral (50%)

The manager is selectively deploying capital with four new catalyst-driven positions while maintaining conviction in existing holdings. The strategy shift toward more positions with near-term catalysts suggests continued deployment but with greater selectivity. The manager is also actively engaging sell-side to change narratives on holdings like Burford, indicating proactive positioning. This represents selective adding with clear deployment bias, scoring in the meaningfully positive range.

Language Signal

55%

BearishBullish

Balanced (55%)

Language is predominantly opportunity-focused with extensive discussion of mispricings, catalysts, and upside scenarios across Burford, Hagerty, Cellebrite, and special situations. Terms like 'unusually well positioned,' 'swift and strong,' 'exceptional returns,' and specific upside targets dominate. Risk language is present but secondary, focused on sector headwinds rather than portfolio-specific concerns. The balance tilts meaningfully toward bullish directional language on specific holdings.

Perceived Risk

52%

Low RiskElevated

Moderate Risk (52%)

The manager acknowledges sector-specific headwinds with software, insurance, and alternative assets underperforming despite strong fundamentals. Multiple compression across holdings is noted as a meaningful challenge. However, risk discussion is focused on sector rotation and valuation pressure rather than systemic concerns. The manager frames these as creating opportunity rather than requiring defensive positioning. Risk acknowledgment is moderate and specific rather than broad or alarming, placing this in the middle of the range.

Opportunity Density

68%

ScarceAbundant

Abundant (68%)

The manager sees abundant opportunities across multiple holdings with specific mispricings identified in Burford (protein cases unrecognized), Hagerty (State Farm acceleration underestimated), Cellebrite (AI winner narrative shift), and special situations. Four new investments were initiated, and the manager states 'we are going to keep looking and turning over rocks.' The tone suggests a rich opportunity set in specific areas despite sector headwinds, warranting a score in the selective-to-good range.

Time Horizon

42%

Short-TermLong-Term

Multi-Year (42%)

The manager explicitly emphasizes near-term catalysts, stating 'We will not need years to learn whether our differentiated views are right' and 'A lot of these situations should settle over the next year.' Specific 12-month catalysts are identified for Burford (2027 trials), Hagerty (2026-2027 guidance beats), Cellebrite (Genesis revenue), and special situations. The strategic shift toward 'more investments with identifiable near-term catalysts' and profit-taking after Liquidia's 30% gain indicate a 1-2 year thesis horizon rather than multi-year patience, placing this in the short-to-medium term range.